Paragon Bioservices Acquires Systems for Use in Vaccine and Protein Manufacturing
News Jan 30, 2013
MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs. The initial application of MaxCyte STX and VLX systems will be in fulfillment of a Department of Defense contract for the process development and manufacturing scale-up of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses in support of the ongoing preclinical evaluation of the efficacy, potency, and safety of these Filovirus vaccine candidates.
“MaxCyte flow electroporation is the ideal transfection technology to meet Paragon’s needs for rapid protein development and production from mammalian and insect cells. The performance and scalability from the MaxCyte STX in the development stage to the MaxCyte VLX at full-scale manufacturing streamlines and accelerates the services we can offer to our clients,” says Marco Chacon, PhD, President and CEO of Paragon. “We believe that this platform will play a key role where performance and rapid response are necessary to meet the scientific and business objectives of our clients, while protecting human and animal health.”
“The ability to transiently transfect 2E11 mammalian cells with RNA or DNA using a single 30 minute run is unique in the industry and aligns perfectly with Paragon’s expertise in protein, virus, and vaccine production. We are delighted that Paragon values the speed, robustness, and scalability of MaxCyte transfection systems,” says Douglas Doerfler, President and CEO of MaxCyte. “With the addition of the MaxCyte STX and MaxCyte VLX, Paragon will be well positioned to provide a streamlined process to meet the development and manufacturing needs of all its global service clients.”
Comments | 0 ADD COMMENT
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
News Jan 12, 2017